JP Morgan Chase’s Definium Therapeutics DFTX Stock Holding History
Bought
Maintained
Sold
Other funds holding DFTX
JP Morgan Chase's DFTX Position: Q3 2026 in Review
JP Morgan Chase increased its Definium Therapeutics (DFTX) stake by 27% in Q3 2026, buying an estimated $3M and bringing the position to 337,191 shares worth $12.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2616.
JP Morgan Chase first reported a position in DFTX in Q2 2021 and has held it in 22 quarters since. 354 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.
- JP Morgan Chase held 337,191 shares of Definium Therapeutics worth $12.9M as of Q3 2026.
- JP Morgan Chase bought 71,236 Definium Therapeutics shares in Q3 2026, an estimated $3M.
- Definium Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #2616 holding.
- JP Morgan Chase first reported a position in Definium Therapeutics in Q2 2021 and has held it in 22 quarters since.
- 354 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.
Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.